Halozyme's 2017 Includes PEGPH20 Milestones, New Partnership
Halozyme CEO Helen Torley spoke with Scrip about execution of the company's strategy – reworked after her arrival in 2014 – to focus on oncology drug development and partnerships using its Enhanze platform.
You may also be interested in...
Original new drugs and biologics recently approved by US FDA.
Two biopharma IPOs in the US continue streak of (mostly) positive returns; two new European VC funds launch as Irish antibiotic developer raises $65m; and Halozyme, Ziopharm price offerings.
Pfizer discontinued its late-stage PCSK9 inhibitor bococizumab after seeing 52-week data showing an unanticipated attenuation of LDL-cholesterol lowering and a higher level of immunogenicity, raising questions about what the impact could be for Amgen’s Repatha and Sanofi/Regeneron’s Praluent.